NeoGenomics, Inc.
DE ˙ DB ˙ US64049M2098
€ 8,62 ↑0.03 (0.35%)
2026-06-04
PREÇO DA AÇÃO
SecurityDE:NG9 / NeoGenomics, Inc.
InstitutionJanus Henderson Group Plc
Latest Disclosed Ownership6,165,063 shares
Ownership 4.80%
Janus Henderson Group Plc ownership in NG9 / NeoGenomics, Inc.

2025-02-14 - Janus Henderson Group Plc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,165,063 shares of NeoGenomics, Inc. (DE:NG9). This represents 4.8 percent ownership of the company. In their previous filing dated 2024-11-14 , Janus Henderson Group Plc had reported owning 6,603,180 shares, indicating a decrease of -6.63 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2025-02-14 2025-02-14 13G/A 6,603,180 6,165,063 -6.63 4.80 -7.69
2024-11-14 2024-11-14 13G 3,472,040 6,603,180 90.18 5.20 57.58
2020-02-14 2020-02-14 13G/A 5,888,667 3,472,040 -41.04 3.30 -47.62
2019-02-12 2019-02-12 13G/A 5,574,112 5,888,667 5.64 6.30 -10.00
2018-02-13 2018-02-13 13G 5,574,112 5,574,112 0.00 7.00 0.00
2018-02-12 2018-02-12 13G 5,574,112 7.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 NEOGENOMICS COM NEW 64049M209 60,110 0 0.00 446 -36.83 0.0001
2026-05-15 2026-03-31 13F NEOGENOMICS COM NEW 64049M209 60,110 0 446 0.0001
2026-02-17 2025-12-31 13F NEOGENOMICS COM NEW 64049M209 60,110 0 0.00 707 52.48 0.0003
2025-11-14 2025-09-30 13F NEOGENOMICS COM NEW 64049M209 60,110 -1,940,450 -97.00 464 -96.83 0.0002
2025-08-14 2025-06-30 13F NEOGENOMICS COM NEW 64049M209 2,000,560 -3,740,466 -65.15 14,624 -73.52 0.0072
2025-05-15 2025-03-31 13F NEOGENOMICS COM NEW 64049M209 5,741,026 -424,037 -6.88 55,229 -45.64 0.0303
2025-02-14 2024-12-31 13F NEOGENOMICS COM NEW 64049M209 6,165,063 -438,117 -6.63 101,600 4.32 0.0516
2024-11-14 2024-09-30 13F NEOGENOMICS COM NEW 64049M209 6,603,180 -16,156 -0.24 97,397 6.08 0.0499
2024-08-14 2024-06-30 13F NEOGENOMICS COM NEW 64049M209 6,619,336 338,470 5.39 91,810 -7.01 0.0492
2024-05-15 2024-03-31 13F NEOGENOMICS COM NEW 64049M209 6,280,866 -67,747 -1.07 98,735 -3.88 0.0539
2024-02-14 2023-12-31 13F NEOGENOMICS COM NEW 64049M209 6,348,613 -825,814 -11.51 102,720 16.40 0.0613
2023-11-14 2023-09-30 13F NEOGENOMICS COM NEW 64049M209 7,174,427 -415,060 -5.47 88,247 -27.64 0.0578
2023-08-14 2023-06-30 13F NEOGENOMICS COM NEW 64049M209 7,589,487 165,135 2.22 121,961 -5.64 0.0758
2023-05-15 2023-03-31 13F NEOGENOMICS COM NEW 64049M209 7,424,352 1,298,581 21.20 129,255 128.39 0.0852
2023-02-14 2022-12-31 13F NEOGENOMICS COM NEW 64049M209 6,125,771 164,627 2.76 56,595 10.26 0.0404
2023-01-13 2022-09-30 13F/A-1 NEOGENOMICS COM NEW 64049M209 5,961,144 4,915,452 470.07 51,329 502.31 0.0385
2022-11-14 2022-09-30 13F NEOGENOMICS COM NEW 64049M209 5,961,144 4,915,452 51,329 0.0384
2022-08-15 2022-06-30 13F NEOGENOMICS COM NEW 64049M209 1,045,692 -3,239,416 -75.60 8,522 -83.63 0.0059
2022-05-16 2022-03-31 13F NEOGENOMICS COM NEW 64049M209 4,285,108 -103,011 -2.35 52,064 -65.23 0.0251
2022-02-14 2021-12-31 13F NEOGENOMICS COM NEW 64049M209 4,388,119 15,623 0.36 149,723 -29.02 0.0624
2021-11-16 2021-09-30 13F NEOGENOMICS COM NEW 64049M209 4,372,496 -54,742 -1.24 210,929 5.48 0.0922
2021-08-16 2021-06-30 13F NEOGENOMICS COM NEW 64049M209 4,427,238 323,454 7.88 199,978 1.04 0.0856
2021-05-17 2021-03-31 13F NEOGENOMICS COM NEW 64049M209 4,103,784 1,386,761 51.04 197,926 35.30 0.0904
2021-02-16 2020-12-31 13F NEOGENOMICS COM NEW 64049M209 2,717,023 36,992 1.38 146,285 47.96 0.0680
2020-11-16 2020-09-30 13F NEOGENOMICS COM NEW 64049M209 2,680,031 -60,939 -2.22 98,866 16.43 0.0515
2020-08-14 2020-06-30 13F NEOGENOMICS COM NEW 64049M209 2,740,970 -53,299 -1.91 84,915 10.06 0.0477
2020-05-14 2020-03-31 13F NEOGENOMICS COM NEW 64049M209 2,794,269 -677,771 -19.52 77,150 -24.03 0.0531
2020-02-18 2019-12-31 13F NEOGENOMICS COM NEW 64049M209 3,472,040 -179,341 -4.91 101,557 45.47 0.0520
2019-11-14 2019-09-30 13F NEOGENOMICS COM NEW 64049M209 3,651,381 -341,825 -8.56 69,814 -20.31 0.0378
2019-07-31 2019-06-30 13F NEOGENOMICS COM NEW 64049M209 3,993,206 -1,107,082 -21.71 87,611 -16.04 0.0477
2019-04-30 2019-03-31 13F NEOGENOMICS COM NEW 64049M209 5,100,288 -788,379 -13.39 104,352 40.53 0.0578
2019-02-06 2018-12-31 13F NEOGENOMICS COM NEW 64049M209 5,888,667 -215,808 -3.54 74,256 -20.75 0.0474
2018-11-09 2018-09-30 13F NEOGENOMICS COM NEW 64049M209 6,104,475 -53,730 -0.87 93,704 16.07 0.0501
2018-08-10 2018-06-30 13F NEOGENOMICS COM NEW 64049M209 6,158,205 -67,909 -1.09 80,734 58.91 0.0460
2018-05-14 2018-03-31 13F NEOGENOMICS COM NEW 64049M209 6,226,114 652,002 11.70 50,805 2.87 0.0299
2018-03-12 2017-12-31 13F/A-1 NEOGENOMICS COM NEW 64049M209 5,574,112 2,109,457 60.89 49,387 28.07 0.0304
2018-02-09 2017-12-31 13F NEOGENOMICS COM NEW 64049M209 5,574,112 2,109,457 49,387
2017-11-14 2017-09-30 13F NEOGENOMICS COM NEW 64049M209 3,464,655 1,159,888 50.33 38,562 86.73 0.0247
2017-08-17 2017-06-30 13F/A-1 NEOGENOMICS COM NEW 64049M209 2,304,767 2,304,767 20,651 0.0141
2017-08-14 2017-06-30 13F NEOGENOMICS COM NEW 64049M209 2,304,767 20,651 0.0141
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.